ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity

Stakišaitis,Donatas; Juknevičienė,Milda; Ulys,Albertas; Žaliūnienė,Dalia; Stanislovaitienė,Daiva; Šepetienė,Ramunė; Slavinska,Anželika; Sužiedėlis,Kęstutis; Lesauskaitė,Vita

doi:10.3892/ol.2018.8749

ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity

Authors:
- Donatas Stakišaitis
- Milda Juknevičienė
- Albertas Ulys
- Dalia Žaliūnienė
- Daiva Stanislovaitienė
- Ramunė Šepetienė
- Anželika Slavinska
- Kęstutis Sužiedėlis
- Vita Lesauskaitė
View Affiliations

Affiliations: Laboratory of Molecular Oncology, National Cancer Institute, LT‑08660 Vilnius, Lithuania, Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, LT‑44307 Kaunas, Lithuania, Oncosurgery Clinics, National Cancer Institute, LT‑08660 Vilnius, Lithuania, Department of Ophtalmology, Medical Academy, Lithuanian University of Health Sciences, LT‑44307 Kaunas, Lithuania, National Blood Center, LT‑10210 Vilnius, Lithuania, Department of Geriatrics, Medical Academy, Lithuanian University of Health Sciences, LT‑44307 Kaunas, Lithuania
Published online on: May 21, 2018 https://doi.org/10.3892/ol.2018.8749
Pages: 1321-1331

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the ABO blood group polymorphism association with prostate, bladder and kidney cancer, and longevity. The following data groups were analyzed: Prostate cancer (n=2,200), bladder cancer (n=1,530), renal cell cancer (n=2,650), oldest‑old (n=166) and blood donors (n=994) groups. The data on the ABO blood type frequency and odds ratio in prostate cancer patients revealed a significantly higher blood group B frequency (P<0.05); the pooled men and women, separate men bladder cancer risk was significantly associated with the blood group B (P<0.04); however, no such association was identified in the female patients. The blood group O was observed to have a significantly decreased risk of bladder cancer for females (P<0.05). No significance for the ABO blood group type in the studied kidney cancer patients was identified. A comparison of the oldest‑old and blood donor groups revealed that blood group A was significantly more frequent and blood type B was significantly rarer in the oldest‑olds (P<0.05). The results of the present study indicated that blood type B was associated with the risk of prostate and bladder cancer, and could be evaluated as a determinant in the negative assocation with longevity. Blood types O and A may be positive factors for increasing the oldest‑old age likelihood. The clustering analysis by the ABO type frequency demonstrated that the oldest‑olds comprised a separate cluster of the studied groups.

View Figures

View References

1	Rummel SK and Ellsworth RE: The role of the histoblood ABO group in cancer. Future Sci OA. 2:FSO1072016. View Article : Google Scholar : PubMed/NCBI
2	Stakisaitis D, Lesauskaitė V, Girdauskaitė M, Janulionis E, Ulys A and Benetis R: Investigation of vitamin D-binding protein polymorphism impact on coronary artery disease and relationship with longevity: Own data and a review. Int J Endocrinol. 2016:83473792016. View Article : Google Scholar : PubMed/NCBI
3	Clausen H and Hakomori SI: ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sang. 56:1–20. 1989. View Article : Google Scholar : PubMed/NCBI
4	Dean L: ABO Blood Group. In: Medical genetics summaries [internet]. Pratt V, McLeod H, Dean L, Malheiro A and Rubinstein W: National Center for Biotechnology Information. Bethesda, MD; 2012, https://www.ncbi.nlm.nih.gov/books/NBK100894/Updated 2015.
5	Hamosh A, Scott AF, Amberger J, Bocchini C, Valle D and McKusick VA: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 30:52–55. 2002. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto F, Cid E, Yamamoto M and Blancher A: ABO research in the modern era of genomics. Transfus Med Rev. 26:103–118. 2012. View Article : Google Scholar : PubMed/NCBI
7	Mourant AE: Blood relations: Blood groups and anthropology. Oxford University Press; Oxford; pp. 13–20. 1983
8	Maynard CL, Elson CO, Hatton RD and Weaver CT: Reciprocal interactions of the intestinal microbiota and immune system. Nature. 489:231–241. 2012. View Article : Google Scholar : PubMed/NCBI
9	de Mattos LC: Structural diversity and biological importance of ABO, H, Lewis and secretor histo-blood group carbohydrates. Rev Bras Hematol Hemoter. 38:331–340. 2016. View Article : Google Scholar : PubMed/NCBI
10	Aird I, Bentall HH and Roberts JA: A relationship between cancer of stomach and the ABO blood groups. Br Med J. 1:799–801. 1953. View Article : Google Scholar : PubMed/NCBI
11	Xu YQ, Jiang TW, Cui YH, Zhao YL and Qiu LQ: Prognostic value of ABO blood group in patients with gastric cancer. J Surg Res. 201:188–195. 2016. View Article : Google Scholar : PubMed/NCBI
12	Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K and Jacobs EJ: et alGenome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 41:986–990. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ben Q, Liu J, Wang W, Guo F, Yao W, Zhong J and Yuan Y: Association between ABO blood types and sporadic pancreatic neuroendocrine tumors in the Chinese Han population. Oncotarget. 8:54799–54808. 2017. View Article : Google Scholar : PubMed/NCBI
14	Engin H, Bilir C, Üstün H and Gökmen A: ABO blood group and risk of pancreatic cancer in a Turkish population in Western Black Sea region. Asian Pac J Cancer Prev. 13:131–133. 2012. View Article : Google Scholar : PubMed/NCBI
15	El Jellas K, Hoem D, Hagen KG, Kalvenes MB, Aziz S, Steine SJ, Immervoll H, Johansson S and Molven A: Associations between ABO blood groups and pancreatic ductal adenocarcinoma: Influence on resection status and survival. Cancer Med. 6:1531–1540. 2017. View Article : Google Scholar : PubMed/NCBI
16	Vasan SK, Hwang J, Rostgaard K, Nyrén O, Ullum H, Pedersen OBV, Erikstrup C, Melbye M, Hjalgrim H, Pawitan Y and Edgren G: ABO blood group and risk of cancer: A register-based cohort study of 1.6 million blood donors. Cancer Epidemiol. 44:40–43. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hakomori S: Antigen structure and genetic basis of histo-blood groups A, B and O: Their changes associated with human cancer. Biochim Biophys Acta. 1473:247–266. 1999. View Article : Google Scholar : PubMed/NCBI
18	Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B and Clément M: ABH and Lewis histo-blood group antigens in cancer. APMIS. 109:9–31. 2001. View Article : Google Scholar : PubMed/NCBI
19	Franchini M, Liumbruno GM and Lippi G: The prognostic value of ABO blood group in cancer patients. Blood Transfus. 14:434–440. 2016.PubMed/NCBI
20	Freudenberg-Hua Y, Freudenberg J, Vacic V, Abhyankar A, Emde AK, Ben-Avraham D, Barzilai N, Oschwald D, Christen E and Koppel J: et alDisease variants in genomes of 44 centenarians. Mol Genet Genomic Med. 2:438–450. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sebastiani P, Riva A, Montano M, Pham P, Torkamani A, Scherba E, Benson G, Milton JN, Baldwin CT and Andersen S: et alWhole genome sequences of a male and female supercentenarian, ages greater than 114 years. Front Genet. 2:902012. View Article : Google Scholar : PubMed/NCBI
22	Fortney K, Dobriban E, Garagnani P, Pirazzini C, Monti D, Mari D, Atzmon G, Barzilai N, Franceschi C, Owen AB and Kim SK: Genome-wide scan informed by age-related disease identifies loci for exceptional human longevity. PLoS Genet. 11:e10057282015. View Article : Google Scholar : PubMed/NCBI
23	Christensen K, Johnson TE and Vaupel JW: The quest for genetic determinants of human longevity: Challenges and insights. Nat Rev Genet. 7:436–448. 2006. View Article : Google Scholar : PubMed/NCBI
24	Spitsyn VA and Stakishaĭtis DV: Interrelation of genetic dimorphism of ear wax and the level of apolipoproteins with atherogenesis and longevity in the Lithuanian population. Genetika. 29:334–341. 1993.(In Russian). PubMed/NCBI
25	Stakishaĭtis DV, Ianchauskene SM, Ivashkiavichene LI and Priaĭksha RA: Atherogenesis and serum levels of apolipoprotein E. Kardiologija. 32:14–16. 1992.
26	Stakisaitis D, Maksvytis A, Benetis R and Viikmaa M: Coronary atherosclerosis and blood groups of ABO system in women (own data and review). Medicina (Kaunas). 38(Suppl 2): S230–S235. 2002.
27	Stini WA: Sex differences in bone loss-an evolutionary perspective on a clinical problem. Coll Antropol. 27:23–46. 2003.PubMed/NCBI
28	Znaor A, Laversanne M and Bray F: Less overdiagnosis of kidney cancer? an age-period-cohort analysis of incidence trends in 16 populations worldwide. Int J Cancer. 141:925–932. 2017. View Article : Google Scholar : PubMed/NCBI
29	Gondos A, Krilaviciute A, Smailyte G, Ulys A and Brenner H: Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. Eur J Cancer. 51:1630–1637. 2015. View Article : Google Scholar : PubMed/NCBI
30	Huffman DM, Deelen J, Ye K, Bergman A, Slagboom EP, Barzilai N and Atzmon G: Distinguishing between longevity and buffered-deleterious genotypes for exceptional human longevity: The case of the MTP gene. J Gerontol A Biol Sci Med Sci. 67:1153–1160. 2012. View Article : Google Scholar : PubMed/NCBI
31	vB Hjelmborg J, Iachine I, Skytthe A, Vaupel JW, McGue M, Koskenvuo M, Kaprio J, Pedersen NL and Christensen K: Genetic influence on human lifespan and longevity. Hum Genet. 119:312–321. 2006. View Article : Google Scholar : PubMed/NCBI
32	Bodmer W: Genetic characterization of human populations: From ABO to a genetic map of the British people. Genetics. 199:267–279. 2015. View Article : Google Scholar : PubMed/NCBI
33	Garratty G, Glynn SA and McEntire R; Retrovirus Epidemiology Donor Study: ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion. 44:703–706. 2004. View Article : Google Scholar : PubMed/NCBI
34	Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM and Giovannucci E: et alABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 75:1677–1681. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kvist E, Krogh J and Hjortberg P: Prognostic variables in patients with prostate cancer: Influence of blood group ABO (H), the Rhesus system, age, differentiation, tumour stage and metastases. Int Urol Nephrol. 24:417–423. 1992. View Article : Google Scholar : PubMed/NCBI
36	Ohno Y, Ohori M, Nakashima J, Okubo H, Satake N, Takizawa I, Hashimoto T, Hamada R, Nakagami Y, Yoshioka K and Tachibana M: Associations between ABO blood groups and biochemical recurrence after radical prostatectomy. Int J Clin Exp Med. 8:2642–2648. 2015.PubMed/NCBI
37	Muthana SM, Gulley JL, Hodge JW, Schlom J and Gildersleeve JC: ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget. 6:32244–32256. 2015. View Article : Google Scholar : PubMed/NCBI
38	Abel PD, Marsh C, Henderson D, Leathem A, Powell PH and Williams G: Detection of blood group antigens in frozen sections of prostatic epithelium. Br J Urol. 59:430–435. 1987. View Article : Google Scholar : PubMed/NCBI
39	Chastonay P, Hurlimann J and Gardiol D: Biological tissue markers in benign and malignant disease of the human prostate. Virchows Arch A Pathol Anat Histopathol. 410:221–229. 1986. View Article : Google Scholar : PubMed/NCBI
40	Li Q, Anver MR, Butcher DO and Gildersleeve JC: Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther. 8:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
41	Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO and Scher HI: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 21:4292–4298. 2003. View Article : Google Scholar : PubMed/NCBI
42	Hirohashi S, Clausen H, Yamada T, Shimosato Y and Hakomori S: Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and −81 expressed in cancer of blood group O or B individuals: Its identification as Tn antigen. Proc Natl Acad Sci USA. 82:7039–7043. 1985. View Article : Google Scholar : PubMed/NCBI
43	Clyne M: Prostate cancer: Non-O blood type is VTE risk factor after radical prostatectomy. Nat Rev Urol. 10:6802013. View Article : Google Scholar : PubMed/NCBI
44	Raitanen MP and Tammela TL: Relationship between blood groups and tumour grade, number, size, stage, recurrence and survival in patients with transitional cell carcinoma of the bladder. Scand J Urol Nephrol. 27:343–347. 1993. View Article : Google Scholar : PubMed/NCBI
45	Chang SS: Re: The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. J Urol. 196:3522016. View Article : Google Scholar : PubMed/NCBI
46	Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI and Lotan Y: et alImpact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol. 191:1238–1243. 2014. View Article : Google Scholar : PubMed/NCBI
47	Yamada T, Fukui I, Yokokawa M and Oshima H: A study of prognosis and clinicopathology of bladder cancer to blood group type of host patients in Japan. Scand J Urol Nephrol. 27:199–203. 1993. View Article : Google Scholar : PubMed/NCBI
48	Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M and Shariat SF: Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol. 32:625–630. 2014. View Article : Google Scholar : PubMed/NCBI
49	Süer E, Özcan C, Gökçe I, Gülpınar Ö, Göğüş C, Türkölmez K, Baltac S and Bedük Y: Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol. 46:1521–1526. 2014. View Article : Google Scholar : PubMed/NCBI
50	Foresto P, Bioindi C, Racca L, Brufman A, Yaber F, Solis E, Provenzal O and Valverde J: Abnormal glycosylation of soluble ABH antigens in tumors of the urinary tract. Arch Esp Urol. 53:196–199. 2000.(In Spanish). PubMed/NCBI
51	Chihara Y, Sugano K, Kobayashi A, Kanai Y, Yamamoto H, Nakazono M, Fujimoto H, Kakizoe T, Fujimoto K, Hirohashi S and Hirao Y: Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest. 85:895–907. 2005. View Article : Google Scholar : PubMed/NCBI
52	Engel O, Soave A, Peine S, Kluth LA, Schmid M, Shariat SF, Dahlem R, Fisch M and Rink M: The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol. 33:1769–1776. 2015. View Article : Google Scholar : PubMed/NCBI
53	Sun W, Wen CP, Lin J, Wen C, Pu X, Huang M, Tsai MK, Tsao CK, Wu X and Chow WH: ABO blood types and cancer risk-a cohort study of 339,432 subjects in Taiwan. Cancer Epidemiol. 39:150–156. 2015. View Article : Google Scholar : PubMed/NCBI
54	Joh HK, Cho E and Choueiri TK: ABO blood group and risk of renal cell cancer. Cancer Epidemiol. 36:528–532. 2012. View Article : Google Scholar : PubMed/NCBI
55	Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA and Clark PE: ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 110:E641–E646. 2012. View Article : Google Scholar : PubMed/NCBI
56	de Martino M, Waldert M, Haitel A, Schatzl G, Shariat SF and Klatte T: Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). BJU Int. 113:E62–E66. 2014. View Article : Google Scholar : PubMed/NCBI
57	Lee C, You D, Sohn M, Jeong IG, Song C, Kwon T, Hong B, Hong JH, Ahn H and Kim CS: Prognostic value of ABO blood group in patients with renal cell carcinoma: Single-institution results from a large cohort. J Cancer Res Clin Oncol. 141:1441–1447. 2015. View Article : Google Scholar : PubMed/NCBI
58	Soyupek S, Tulunay O, Armağan A, Hoscan B and Perk H: Clinical importance of intratumoral and normal renal parenchymal inflammatory cell infiltration in renal cell carcinoma. Scand J Urol Nephrol. 41:387–391. 2007. View Article : Google Scholar : PubMed/NCBI
59	Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C and Timotheadou E: et alTumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 25:4542–4549. 2007. View Article : Google Scholar : PubMed/NCBI
60	Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, Rafferty I, Lauretani F, Murray A, Gibbs JR and Paolisso G: et alA genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4:e10000722008. View Article : Google Scholar : PubMed/NCBI
61	Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Vallvé C, Borrell M, Urrutia T and Fontcuberta J: The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 93:468–474. 2005.PubMed/NCBI
62	Iodice S, Maisonneuve P, Botteri E, Sandri MT and Lowenfels AB: ABO blood group and cancer. Eur J Cancer. 46:3345–3350. 2010. View Article : Google Scholar : PubMed/NCBI
63	Cordon-Cardo C, Reuter VE, Finstad CL, Sheinfeld J, Lloyd KO, Fair WR and Melamed MR: Blood group-related antigens in human kidney: Modulation of Lewis determinants in renal cell carcinoma. Cancer Res. 49:212–218. 1989.PubMed/NCBI
64	Reid ME and Mohandas N: Red blood cell blood group antigens: Structure and function. Semin Hematol. 41:93–117. 2004. View Article : Google Scholar : PubMed/NCBI
65	Hofmann BT, Stehr A, Dohrmann T, Güngör C, Herich L, Hiller J, Harder S, Ewald F, Gebauer F and Tachezy M: et alABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Clin Cancer Res. 20:6117–6126. 2014. View Article : Google Scholar : PubMed/NCBI
66	Ju T, Otto VI and Cummings RD: The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl. 50:1770–1791. 2011. View Article : Google Scholar : PubMed/NCBI
67	Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO and Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer. 73:50–56. 1997.
68	Hakomori S: Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines. Adv Exp Med Biol. 491:369–402. 2001. View Article : Google Scholar : PubMed/NCBI
69	Williams SR, Hsu FC, Keene KL, Chen WM, Dzhivhuho G, Rowles JL III, Southerland AM, Furie KL, Rich SS and Worrall BB: et alGenetic drivers of von Willebrand factor levels in an ischemic stroke population and association with risk for recurrent stroke. Stroke. 48:1444–1450. 2017. View Article : Google Scholar : PubMed/NCBI
70	Franchini M, Crestani S, Frattini F, Sissa C and Bonfanti C: ABO blood group and von Willebrand factor: Biological implications. Clin Chem Lab Med. 52:1273–1276. 2014. View Article : Google Scholar : PubMed/NCBI
71	Franchini M, Frattini F, Crestani S, Bonfanti C and Lippiet G: Von Willebrand factor and cancer: A renewed interest. Thromb Res. 131:290–292. 2013. View Article : Google Scholar : PubMed/NCBI
72	Furnari FB, Cloughesy TF, Cavenee WK and Mischel PS: Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 15:302–310. 2015. View Article : Google Scholar : PubMed/NCBI
73	Breier G, Grosser M and Rezaei M: Endothelial cadherins in cancer. Cell Tissue Res. 355:523–527. 2014. View Article : Google Scholar : PubMed/NCBI
74	Prochazka L, Tesarik R and Turanek J: Regulation of alternative splicing of CD44 in cancer. Cell Signal. 26:2234–2239. 2014. View Article : Google Scholar : PubMed/NCBI
75	Akhtar K, Mehdi G, Sherwani R and Sofi L: Relationship between various cancers and ABO blood groups-a Northern India experience. Internet J Pathol. 13:12010.
76	Paré G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, Miletich JP and Ridkeret PM: Novel association of ABO histo-blood group antigen with soluble ICAM-1: Results of a genome-wide association study of 6,578 women. PLoS Genet. 4:e10001182008. View Article : Google Scholar : PubMed/NCBI
77	Zhang W, Xu Q, Zhuang Y and Chen Y: Novel association of soluble intercellular adhesion molecule 1 and soluble P-selectin with the ABO blood group in a Chinese population. Exp Ther Med. 12:909–914. 2016. View Article : Google Scholar : PubMed/NCBI
78	Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, Nambi V, Bretler M, Smith NL and Peters A: et alLarge-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 19:1863–1872. 2010. View Article : Google Scholar : PubMed/NCBI
79	Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B and Sun L: et alGenome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 29:1958–1967. 2009. View Article : Google Scholar : PubMed/NCBI
80	Qi L, Cornelis MC, Kraft P, Jensen M, van Dam RM, Sun Q, Girman CJ, Laurie CC, Mirel DB and Hunter DJ: et alGenetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet. 19:1856–1862. 2010. View Article : Google Scholar : PubMed/NCBI
81	Franchini M, Favaloro EJ, Targher G and Lippi G: ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci. 49:137–149. 2012. View Article : Google Scholar : PubMed/NCBI
82	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
83	Rieckmann P, Michel U, Albrecht M, Brück W, Wöckel L and Felgenhauer K: Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol. 60:9–15. 1995. View Article : Google Scholar : PubMed/NCBI
84	Kobayashi H, Boelte KC and Lin PC: Endothelial cell adhesion molecules and cancer progression. Curr Med Chem. 14:377–386. 2007. View Article : Google Scholar : PubMed/NCBI
85	Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, Büchler MW and Weitz J: AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 12:3192012. View Article : Google Scholar : PubMed/NCBI
86	Ko K, Park YH, Jeong CW, Ku JH, Kim HH and Kwak C: Prognostic significance of blood type A in patients with renal cell carcinoma. Urol J. 13:2765–2772. 2016.PubMed/NCBI
87	Alkout AM, Blackwell CC and Weir DM: Increased inflammatory responses of persons of blood group O to Helicobacter pylori. J Infect Dis. 181:1364–1369. 2000. View Article : Google Scholar : PubMed/NCBI
88	Breimer ME, Mölne J, Nordén G, Rydberg L, Thiel G and Svalander CT: Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation. 82:479–485. 2006. View Article : Google Scholar : PubMed/NCBI
89	Nambiar RK, Narayanan G, Prakash NP and Vijayalakshmi K: Blood group change in acute myeloid leukemia. Proc (Bayl Univ Med Cent). 30:74–75. 2017. View Article : Google Scholar : PubMed/NCBI
90	Ichikawa D, Handa K and Hakomori S: Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer. 76:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
91	Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T and Pottier G: et alPredictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res. 6:1125–1134. 2000.PubMed/NCBI
92	Greenwell P: Blood group antigens: Molecules seeking a function? Glycoconj J. 14:159–173. 1997. View Article : Google Scholar : PubMed/NCBI
93	Halloran MM, Carley WW, Polverini PJ, Haskell CJ, Phan S, Anderson BJ, Woods JM, Campbell PL, Volin MV, Bäcker AE and Koch AE: Ley/H: An endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol. 164:4868–4877. 2000. View Article : Google Scholar : PubMed/NCBI
94	Yamamoto F, McNeill PD and Hakomori S: Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun. 187:366–374. 1992. View Article : Google Scholar : PubMed/NCBI
95	Cozzi GD, Levinson RT, Toole H, Snyder MR, Deng A, Crispens MA, Khabele D and Beeghly-Fadiel A: Blood type, ABO genetic variants, and ovarian cancer survival. PLoS One. 12:e01751192017. View Article : Google Scholar : PubMed/NCBI
96	Trégouët DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D and Juhan-Vague I: et alCommon susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: Results from a GWAS approach. Blood. 113:5298–5303. 2009. View Article : Google Scholar : PubMed/NCBI
97	Ozel AB, McGee B, Siemieniak D, Jacobi PM, Haberichter SL, Brody LC, Mills JL, Molloy AM, Ginsburg D, Li JZ and Desch KC: Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance. J Thromb Haemost. 14:1888–1898. 2016. View Article : Google Scholar : PubMed/NCBI
98	Murray S: ABO groups and Rh genotypes in the elderly. Br Med J. 2:1472–1474. 1961. View Article : Google Scholar : PubMed/NCBI
99	Matsui T, Titani K and Mizuochi T: Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem. 267:8723–8731. 1992.PubMed/NCBI
100	Ohira T, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Zakai NA, Rosamond WD and Folsom AR: ABO blood group, other risk factors and incidence of venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemos. 5:1455–1461. 2007. View Article : Google Scholar
101	Zhou S and Welsby I: Is ABO blood group truly a risk factor for thrombosis and adverse outcomes? World J Cardiol. 6:985–992. 2014. View Article : Google Scholar : PubMed/NCBI
102	Mengoli C, Bonfanti C, Rossi C and Franchini M: Blood group distribution and life-expectancy: A single-centre experience. Blood Transfus. 13:313–317. 2015.PubMed/NCBI
103	Brecher ME and Hay SN: ABO blood type and longevity. Am J Clin Pathol. 135:96–98. 2011. View Article : Google Scholar : PubMed/NCBI
104	Shimizu K, Hirose N, Ebihara Y, Arai Y, Hamamatsu M, Nakazawa S, Masui Y, Inagaki H, Gondo Y and Fujimori J: et alBlood type B might imply longevity. Exp Gerontol. 39:1563–1565. 2004. View Article : Google Scholar : PubMed/NCBI